We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. We execute a clear strategy around the three pillars of Alzheimer's disease, other significant and neuro-orphan indications and diagnosis. Source
No articles found.
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthro...
Eyenovia is a late-stage ophthalmic biopharmace...
We are a vertically integrated, clinical stage gene therapy company with four ongo...
We are a vertically integrated, clinical stage ...
DURECT is a biopharmaceutical company actively developing therapeutics based on it...
DURECT is a biopharmaceutical company actively ...
Join the National Investor Network and get the latest information with your interests in mind.